Sentences with phrase «macular edema»
"Macular edema" refers to a condition where a part of the eye called the macula, which is responsible for sharp central vision, becomes swollen due to fluid accumulation. Full definition
This AI was designed to flag advanced AMD or diabetic macular edema for urgent treatment, and to refer less severe cases for routine checkups.
sciencenews.org
Clearside Biomedical announced that a special formulation of triamcinolone acetonide showed good outcomes in patients with macular edema associated with non-infectious uveitis.
In their study, Dr Cuadros and coauthors sought to determine whether hard exudates in clinic photographs are an accurate indicator of clinically significant macular edema in patients with diabetes.
The dilated exams showed clinically significant macular edema in about 15 percent of patients.
Hard exudates detected on the digital photographs were an accurate indicator of macular edema.
Clearside Biomedical is enrolling participants in a clinical trial evaluating the safety and efficacy of a suprachoroidal injection of triamcinolone acetonide in subjects with macular edema associated with non-infectious uveitis.
Dr. Ashvini Reddy on the benefits of oral acetazolamide for patients with refractory inflammatory macular edema.
The system used machine learning to identify macular degeneration and diabetic macular edema within...
Study participants who were treated with Lucentis were less likely to develop macular edema than those treated with laser therapy.
The new study suggests that VEGF drugs may even help prevent macular edema.
«Drugs are effective for diabetic macular edema new trial shows.»
This increase was found in the Chinese American study participants with Type II diabetes who had cataracts or macular edema resulting in visual impairments.
«High - priced drugs used to treat diabetic macular edema not cost - effective.»
Optometrists and ophthalmologists, with specialized training and instruments, can diagnose macular edema.
8.45 PM Laura J. Kopplin, MD: Peginterferon alfa - 2a (PEGASYS) in the Treatment of Inflammatory Cystoid Macular Edema
These studies have indicated that repeated doses of anti-VEGF medications, such as ranibizumab, may prevent blood vessels from leaking fluid and causing macular edema.
Detailed evidence - based recommendations for prevention, early detection, and treatment by stage of retinopathy with and without macular edema, including a detailed discussion of the relative roles of laser photocoagulation and anti-VEGF therapy in treatment.
Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice.
Clearside Biomedical announced that their proprietary formulation of triamcinolone acetonide (CLS - TA) improved vision in patients with macular edema from noninfectious uveitis.
The photos were sent over the Internet for review by eye specialists, who looked for hard exudates close to the line of sight as an indicator of clinically significant macular edema.
The company is currently in phase 2 testing of a drug that could one day treat diabetic macular edema.
These included age - related macular degeneration, or AMD — a leading cause of vision loss in adults over 50 — and diabetic macular edema, a condition that develops from diabetic retinopathy.
The advent of intravitreous (in the vitreous, the fluid behind the lens in the eye) anti-vascular endothelial growth factor (VEGF) injections to treat common causes of vision loss, such as exudative (wet) age - related macular degeneration (AMD) and diabetic macular edema has improved visual outcomes for many patients.
VEGF inhibitors have been used for several years to treat diabetic macular edema, a swelling of the retina that can occur as blood leaks around it.
About 750,000 Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead.
In the first clinical trial directly comparing three drugs most commonly used to treat diabetic macular edema, researchers found all were effective in improving vision and preventing vision loss.
The study focused on two common causes of irreversible blindness: macular degeneration and diabetic macular edema.
The current standard of clinical care for wet macular degeneration and diabetic macular edema is repeated injections into the eye of antibodies against a protein called VEGF.
The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema.
An equally large number of patients have diabetic macular edema and could also potentially benefit from the treatment.
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost - effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study published online by JAMA Ophthalmology.
In the article, «Utility of Hard Exudates for the Screening of Macular Edema,» using digital photographs of the eye taken at the doctor's office or clinic, eye specialists can reliably detect «hard exudates» — a key early sign of diabetes - related macular edema, reports the new research by Jorge A. Cuadros, OD, PhD, of UC Berkeley School of Optometry and colleagues.
This macular edema is one of the most serious vision - threatening changes in the eyes of people with diabetes.
The study included 103 adults with type 2 diabetes, seen at a public health clinic, who were considered at high risk for macular edema.
Dr Cuadros and coauthors conclude, «Low - cost and reliable methods of detecting clinically significant macular edema, such as the use of a hard exudate surrogate marker described here, are needed to meet the challenge of widespread screening for this vision - threatening condition.»
Because Lucentis is commonly injected to treat diabetic macular edema (DME)-- a build - up of fluid in the center of the retina — the study permitted the use of Lucentis for DME in the laser group, if necessary.
Regeneron Pharmaceuticals this week reported positive results from two phase 3 trials of Eylea (aflibercept) injection for diabetic macular edema (DME).
According to Dr. Aiello, anti-VEGF treatments proved to be approximately twice as effective in improving vision and nearly three times more effective in preventing vision loss from diabetic macular edema than laser treatments.
Additional inhibitors targeting this pathway are under development by multiple pharmaceutical companies for this genetic disease and other conditions, including diabetic macular edema.
One is termed diabetic macular edema, which is caused by increased leakage of the small blood vessels in the back of the eye.